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SUMMARY – LMO2 (LIM domain only) is a member of transcription factor family of proteins 
characterized by their cysteine-rich, zinc-binding LIM domains. Its expression in prostate cancer 
cells, as well as in adjacent stroma, is described in a study in a cohort of 83 patients treated with radi-
cal prostatectomy for clinically localized prostate adenocarcinoma. Authors found that LMO2 over-
expression in prostate cancer was strongly associated with features indicative of worse prognosis 
(higher preoperative PSA, higher Gleason score, positive surgical margins, and extraprostatic exten-
sion of disease). Expression of LMO2 was also associated with biochemical disease progression. We 
analysed immunohistochemical expression of LMO2 in prostate cancer epithelial and stromal cells, as 
well as in adjacent parenchyma. Signifi cant negative correlation between glandular expression of 
LMO2 in carcinoma and stromal expression in BPH (ρ = -0.238, P = 0.033) was found, but also be-
tween stromal expression in carcinomas and glandular expression in BPH (ρ = -0.255, P = 0.021). 
Positive correlation was found between stromal expression in BPH and stromal expression in carcino-
mas (ρ = 0.306, P = 0.005). Study results support the potential role of LMO2 in prostatic carcinogen-
esis and cancer progression.
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Introduction
Prostate carcinoma (PCa) is the most common 
cancer worldwide1. It accounts for approximately 18% 
of all newly diagnosed malignant tumors in males in 
Croatia. It is responsible for up to 10% of all deaths in 
males in 20141,2. Th ere are well established features in-
dicative of worse prognosis, but for some groups of 
PCa we still cannot precisely predict which tumors 
will behave aggressively. Today, it is well-known that 
the interaction between stroma and carcinomatous 
epithelial cells plays an important role in carcinogen-
esis, cancer progression and metastases3. Prostate can-
cer stroma is composed of (myo)fi broblasts, endothe-
lial cells and immune cells. Extracellular matrix is also 
one of the keys for creating a suitable microenviron-
ment for cancer progression3.
LMO2 is a member of transcription factor family 
of proteins characterized by their cysteine-rich, zinc-
binding LIM domains. Its expression is required early 
in hematopoiesis4 and it was fi rst identifi ed in T-cell 
acute lymphoblastic leukaemia (T-ALL)4,5. LMO2 
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proteins are important regulators in controlling cell 
growth and diff erentiation5,6. Its expression is a strong 
predictor of superior outcome in patients with diff use 
large B-cell lymphoma5,6. Recent studies also suggest 
that LMO2 over-expression may be associated with 
several other malignant tumors, including gastric car-
cinoma7, pancreatic carcinoma8 and glioma9.
Th ere are several studies dealing with LMO2 in 
prostate cancer, showing the highest expression of 
LMO2 in prostate carcinoma epithelial cells and stro-
mal cells of the peripheral zone, using immunohisto-
chemistry and RT-PCR methods4,10.
Th e aim of this study was to analyse the expression 
of LMO2 in prostate cancer epithelial cells, normal 
epithelial cells of adjacent prostatic parenchyma, as 
well as stromal cells within tumor tissue and surround-
ing non-tumor area.
Patients and methods
Th e study included 83 patients, median age 66.0 
years (range 62-68 years), treated with radical retropu-
bic prostatectomy for clinically localized prostate ade-
nocarcinoma at the Department of Urology in Sestre 
milosrdnice University Hospital Centre in Zagreb, 
Croatia. All patient identifi ers were removed and re-
placed by unique study numbers, linked to the original 
identifi ers by a single fi le kept under high security. Th e 
retrieval of archival tissue block was conducted under 
institutional review board approval. None of the pa-
tients were treated with hormone or radiation therapy 
before or after radical prostatectomy, and none had 
secondary cancer.
Specimens were fi xed in 10% buff ered formalin, 
embedded in paraffi  n, cut at 5-μm thickness, and rou-
tinely stained with haematoxylin and eosin. Th e diag-
nosis of adenocarcinoma was histologically confi rmed 
in all cases.
Ninety prostate cancer specimens were used to 
construct a tissue microarray by manual tissue arrayer. 
Representative areas of each paraffi  n block were la-
belled by B.K. and M.U. and adequate specimens con-
taining cancer from peripheral zone of the prostate 
were sampled. Haematoxylin and eosin stained sec-
tions from each block were analysed to ensure the col-
lection of adequate tissue. Seven specimens were not 
included into the study due to lack of tumorous tissue 
in the recipient block.
Deparaffi  nization and immunohistochemical stain-
ing were performed following the Microwave Strepta-
vidin ImmunoPeroxidase (MSIP) protocol on a DAKO 
Tech-MateTM Horizon automated immunostainer 
(DAKO, Copenhagen, Denmark). We used primary 
monoclonal antibodies to LMO2 (1F10/B8): sc-73516, 
dilution 1:100, Abcam Cruz Biotechnology, Inc., CA, 
USA). Breast cancer tissue served as positive control 
and the removal of primary antibody was used as nega-
tive control.
To evaluate the intensity of LMO2 expression in 
prostate cancer and adjacent prostatic parenchyma, the 
percentage of positively stained carcinoma cells was 
examined in the entire slide. We applied a system sim-
ilar to that used in a previous study of LMO2 expres-
sion in prostate cancer, where at least moderate stain-
ing intensity was required in more than 25% of tumour 
and/or stromal cells to defi ne LMO2 overexpres-
sion6,10. Staining was graded on a 0-3 scale and ex-
pressed as 0, up to 25% of positive carcinoma or stro-
mal cells; low, 25%-50% of positive carcinoma epithe-
lial/stromal cells; moderate, 50%-75% of positive car-
cinoma epithelial/stromal cells; and high, more than 
75% of positive carcinoma epithelial/stromal cells. All 
samples were examined independently by two observ-
ers (M. U., and B. K.). Any disagreements were re-
solved by a joint review.
Statistical analysis was performed using Mann-
Whitney U test, Kruskal-Wallis test, χ2-test, Kaplan-
Meier test and Cox proportional-hazards regression 
test. Th e levels of statistical signifi cance were set at 
least at p<0.05.
Results
Median patient age was 66.0 (62.0 - 68.0) years. 
Gleason score was under 7 in 18 (21.7%) patients, and 
it was 7 in 50 (60.2%) patients (41 (49.4%) had 3+4 
score, while 9 (10.8%) had 4+3 score). Gleason score 
>7 was recorded in 15 (18.1%) patients.
LMO2 expression in stromal and glandular tissue of 
carcinomas and benign prostate hyperplasia is present-
ed in Table 1 and Figure 1. Overall, patients with BPH 
had lower expression of LMO2 in both stromal and 
glandular tissue (P<0.001). Th ere was no correlation 
between age and Gleason score with LMO2 expression.
LMO2 was expressed in all 83 tissue array speci-
mens of prostate cancer (Table 1 and Fig. 1). Seventy 
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Table 1. LMO2 expression in stromal and glandular tissue 
of carcinomas and adjacent uninvolved prostate tissue.




1 1 (1.2) 0 (0)
2 34 (41.0) 6 (7.2)




0 38 (45.8) 1 (1.2)
1 35 (42.2) 36 (43.4)
2 5 (6.0) 39 (47.0)
3 5 (6.0) 7 (8.4)
Fig. 1. A) Microscopic appearance of benign prostate hyperplasia (HEx200) and B) strong epithelial positive 
staining for LMO2 with less positive stromal cells (200x LMO2). C) Microscopic appearance of prostate 
cancer with D) strong positive cancer epithelial staining and weak stromal staining (200x LMO2)
seven cases (92.8%) showed strong and 7 cases (7.8%) 
showed moderate expression of LMO2 in tumor cells. 
Expression in the epithelium of benign gland in adja-
cent parenchyma was strong in 48 cases (57.8%), mod-
erate in 34 (41.0%) and slight in 1 (1.2%) case. On the 
other hand, strong stromal reaction for LMO2 was 
found in the stromal component of 7 carcinomas, 
moderate in 39, slight staining in 36 cases and negative 
in 1 case only. Negative stromal reaction in adjacent 
benign prostatic tissue was recorded in 38 cases, slight-
ly positive in 35, moderate in 5, while strong positivity 
was recorded in 5 cases. Immunohistochemical reac-
tion was membranous and cytoplasmatic (Fig. 1).
We found a signifi cant negative correlation be-
tween glandular expression of LMO2 in carcinomas 
and stromal expression in BPH (ρ = -0.238, P = 0.033), 
but also between stromal expression in carcinomas and 
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glandular expression in BPH (ρ = -0.255, P = 0.021). 
A positive correlation was found between stromal ex-
pression in BPH and stromal expression in carcinomas 
(ρ = 0.306, P = 0.005).
Discussion
Prostate is divided into peripheral and transitional 
zone, central zone and anterior fi bromuscular stroma, 
by McNeal11. Histologic diff erences between these 
zones are well known, but diff erent molecular features 
of prostatic zones have also been observed and report-
ed12, 13. Alves et al. have recently shown a diff erent pro-
portion of collagen and elastic fi bres, muscle and pe-
ripheral nerves in the peripheral and transitional 
zones14. Similarly, Tomas et al. described diff erences in 
the arrangement of reactive stroma, which occurs in 
prostatic carcinoma, using histochemical staining by 
Mallory method and confi rmed by immunohisto-
chemistry (desmin and vimentin)15. Studies on diff er-
ent human cancer specimens demonstrated activated 
stromal cell phenotypes, modifi ed extracellular matrix 
(ECM) composition, and increased micro-vessel den-
sity similar to stromal changes at the site of wound 
repair3. Numerous molecules and cytokines are in-
volved in cancerous stromal-epithelial interaction and 
are important in providing a suitable microenviron-
ment for cancer progression. One of these molecules is 
LMO29-10,16.
Overexpression of LMO2 was strongly associated 
with advanced tumor stage and metastasis of prostate 
carcinoma4,10. Ma et al. compared the LMO2 expres-
sion in human prostatic tissue, prostate cancer cell 
lines, and xenografts and found that LMO2 may con-
tribute to the development of prostatic adenocarcino-
ma by suppressing E-cadherin expression, a well-
known ECM protein10. A recent study has also sug-
gested that LMO2 is overexpressed in stromal cell and 
cancer-associated fi broblasts of the peripheral zone 
which may contribute to cancer promotion4. It was 
strongly associated with established features indicative 
of worse prognosis, such as higher preoperative PSA 
(p=0.011), higher Gleason score (p<0.001), positive 
surgical margins (p<0.003), and extraprostatic exten-
sion of disease (p<0.003). LMO2 expression was also 
associated with biochemical disease4. Authors suggest 
that this eff ect may be due to stimulation of secretion 
of IL-11, which can activate STAT3 signalling down-
stream via its receptor IL11Rα. Th is is a pathway for 
creating the so-called cancer promoting microenviron-
ment4,5.
Th e aim of our study was to analyse the expression 
of LMO2 in prostate cancer epithelial and stromal 
cells, as well as epithelial cells of normal glands and 
stromal cells of the adjacent prostatic parenchyma. 
Our results were similar in the sense of higher expres-
sion of LMO2 in cancer epithelial cells, as well as stro-
mal cells when compared to BPH. Signifi cant negative 
correlation between expression of LMO2 in carcino-
matous glands and stromal expression in BPH was 
found (ρ = -0.238, P = 0.033), but also between stro-
mal expression in carcinomas and glandular expression 
in BPH (ρ = -0.255, P = 0.021). Overexpression of 
LMO2 wasn’t related to higher Gleason grade or PSA 
and extraprostatic extension.
In conclusion, we believe that LMO2 has a role in 
PCa progression and creation of cancer promoting mi-
croenvironment, but further investigation is needed for 
novel therapeutic possibilities that could off er a micro-
environment-targeted strategy for PCa treatment.
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Sažetak
IZRAŽENOST LMO2 U KARCINOMU PROSTATE I PARENHIMU PROSTATE
B. Krušlin, M. Vučić, S. Mašić, I. Kruljac, C. Lež, B. Ružić, B. Spajić i M. Ulamec
LMO2 (LIM domain only) pripada obitelji proteina transkripcijskih faktora, za koje je karakteristična cink vežuća LIM 
domena bogata cisteinom. Njegova izraženost u karcinomu prostate, kao i u okolnoj stromi određena je u jednoj od studija 
na kohorti od 83 bolesnika nakon radikalne prostatektomije zbog lokaliziranog karcinoma prostate. Povišena izraženost 
LMO2 bila je povezana s pokazateljima lošije prognoze (s višim preoperativnim PSA vrijednostima, višim Gleason zbrojem, 
pozitivnim kirurškim rubovima i širenjem tumora izvan prostate). Izraženost LMO2 bila je povezana i s biokemijskom pro-
gresijom bolesti u univarijantnim analizama. U našem istraživanju analizirana je imunohistokemijska izraženost LMO2 u 
karcinomu prostate, u epitelnim i stromalnim stanicama karcinoma, kao i u okolnom, netumorskom parenhimu prostate. 
Pronađena je značajna negativna korelacija između izraženosti LMO2 u epitelu karcinoma i stromalnoj izraženosti u 
 benignoj hiperplaziji (BPH) (ρ = -0.238, p = 0.033), također i stromalne izraženosti u karcinomu i žlijezdama BPH 
(ρ = -0.255, P = 0.021). Pozitivna korelacija pronađena je između izraženosti LMO2 u stromi BPH i stromi karcinoma 
(ρ = 0.306, P = 0.005). Rezultati ovog istraživanja podupiru moguću ulogu LMO2 u karcinogenezi prostate i progresiji 
 tumora. Nije dobivena povezanost ekspresije LMO-2 i dobi te Gleason zbroja.
Ključne riječi: LMO2; Karcinom prostate; Reakcija strome
